Financial Assistance Options

No matter what type of health insurance your patient has, they may have options to help them afford their medicine. Options may be available to your patient even if they have no insurance at all.

Use our financial assistance tool to see which programs may be right for your patient.

Get started

If you would rather talk through some potential options, call us at 866-4ACCESS (866-422-2377) (6AM-5PM PST, Monday through Friday).

Quick Links

ACTEMRA Co-pay Program

Independent Co-pay Assistance Foundations

Genentech Patient Foundation

Help With Co-pay Costs

These programs help your patient pay for ACTEMRA if they have insurance but still need help with costs:

Help With Costs for ACTEMRA

With the ACTEMRA Co-pay Program, eligible patients with commercial insurance could pay as little as $5 per ACTEMRA treatment. Co-pay assistance is provided up to $15,000 per calendar year.

Your patient may be eligible if they:

Are taking ACTEMRA for an FDA-approved use
Are 18 years of age or older or have a Legally Authorized Person over the age of 18 to manage the program
Have commercial (private or non-governmental) insurance. This includes plans available through state and federal health insurance exchanges
Live and receive treatment in the United States or U.S. Territories
Are not receiving assistance through the Genentech Patient Foundation or any other charitable organization for the same expenses covered by the program
Do not use a state or federal healthcare plan to pay for your medication. This includes, but is not limited to, Medicare, Medicaid and TRICARE

The Co-pay Program (“Program”) is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. Patients using Medicare, Medicaid or any other federal or state government program (collectively, “Government Programs”) to pay for their Genentech medicine are not eligible.

Under the Program, the patient may be required to pay a co-pay. The final amount owed by a patient may be as little as $0 for the Genentech medicine (see Program specific details available at the Program website). The total patient out-of-pocket cost is dependent on the patient’s health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient’s out-of-pocket expenses for the Genentech medicine.

All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. No party may seek reimbursement for all or any part of the benefit received through the Program. The value of the Program is intended exclusively for the benefit of the patient. The funds made available through the Program may only be used to reduce the out-of-pocket costs for the patient enrolled in the Program. The Program is not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented a program that adjusts patient cost-sharing obligations based on the availability of support under the Program and/or excludes the assistance provided under the Program from counting towards the patient’s deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Program. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply from Genentech programs. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time.

Additional terms and conditions apply. Please visit the Co-pay Program website for the full list of Terms and Conditions.

View full TERMS AND CONDITIONS

Apply now

An independent co-pay assistance foundation is a charitable organization providing financial assistance to patients with specific disease states, regardless of treatment. Patients who are commercially or publicly insured, including those covered by Medicare and Medicaid, can contact the foundations directly to request assistance. Eligibility requirements, all aspects of the application process, turnaround times and the type or amount of assistance available (if any) can vary by foundation.

These foundations may be able to help. Please check their websites for up-to-date information.

Advise your patient that these organizations are independent of Genentech and may require the patient to provide personal or financial information directly to the organization to enroll in their respective programs. Genentech cannot share any information the patient has provided to us.

Independent co-pay assistance foundations have their own rules for eligibility. We have no involvement or influence in independent foundation decision-making or eligibility criteria and do not know if a foundation will be able to help your patient. We can only refer your patient to a foundation that supports their disease state. This information is provided as a resource for you. We do not endorse or show preference for any particular foundation. The foundations in this list may not be the only ones that might be able to help your patient.

Genentech Patient Foundation

If patients don’t have health insurance coverage for ACTEMRA or have financial concerns and meet eligibility criteria, this program may help:

The Genentech Patient Foundation gives free ACTEMRA to people who have been prescribed this medicine and don’t have insurance or that have financial concerns and meet certain eligibility criteria.

Your patient may be eligible if their insurance coverage and income match one of these situations:

Uninsured patients with incomes under $150,000
Insured patients without coverage for ACTEMRA with incomes under $150,000
Insured patients with coverage for a Genentech medicine:
- With an out-of-pocket maximum set by their health insurance plan that exceeds 7.5% of their household income
- With household size and income within certain guidelines

For any of these situations, add $25,000 for each extra person in households larger than 4 people.

We encourage insured patients to try other financial assistance options before applying for help from the Genentech Patient Foundation, if possible.

Enrollment Process for the Genentech Patient Foundation

Get started with enrollment by following the steps below.

Option 1: Submit online

If your practice has a registered account for My Patient Solutions, you can get started by logging into your account.

Go to My Patient Solutions

Don't have an account?

Launch Quick Enroll

Your patient is required to complete the Patient Consent Form. You can either upload their Patient Consent Form as part of your application or have your patient submit the form via fax, text or e-submit.

An online tool to help you enroll patients in ACTEMRA Access Solutions and manage your service requests at your convenience.

Option 2: Print & fax or text

Step 1: Print one of the Patient Consent Forms below for your patient to complete.

Step 2: Print and complete the Prescriber Foundation Form below.

Prescriber Foundation Form

Step 3: Submit the completed forms via fax or text.

Send via fax to 833-999-4363
Text a photo of the form to 650-877-1111

Both forms are required. We must have both the Patient Consent Form and the Prescriber Foundation Form before we can help you.

What to expect next:

The request will be processed within five business days upon receipt of both required forms.
Your office will be contacted to discuss any next steps.

If you have any questions about the criteria, please contact a Foundation Specialist at 888-941-3331 (Mon.–Fri., 6AM–5PM PST).

Use our financial assistance tool to see which programs may be right for your patient.

Get started

Commercial insurance: An insurance plan you get from a private health insurance company. This can be insurance from your job, from a plan you bought yourself or from a Health Insurance Marketplace. Medicare and Medicaid are not considered commercial insurance.
Public insurance: A health insurance plan you get from the federal or state government. This includes Medicare, Medicaid, TRICARE and DoD/VA insurance.
For example, a household size of 1 with income of less than $75,000 may meet the criteria for assistance. Add $25,000 for each additional person in the household. There is no maximum number of people you may add.

INDICATIONS

ACTEMRA is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

ACTEMRA is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

ACTEMRA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.

ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.

ACTEMRA is indicated for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).

ACTEMRA is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

RISK OF SERIOUS INFECTIONS:

Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.

Reported infections include:

Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients should be tested for latent tuberculosis before ACTEMRA use and during therapy (except patients with COVID-19). Treatment for latent infection should be initiated prior to ACTEMRA use.
Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.
Bacterial, viral and other infections due to opportunistic pathogens.

The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

CONTRAINDICATION

ACTEMRA is contraindicated in patients with known hypersensitivity to ACTEMRA.

WARNINGS AND PRECAUTIONS

Gastrointestinal Perforations

Events of gastrointestinal (GI) perforation have been reported in clinical trials, primarily as complications of diverticulitis in RA patients. Use ACTEMRA with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with fever, new onset abdominal symptoms, and a change in bowel habits for early identification of GI perforation.

Hepatotoxicity

Serious cases of hepatic injury have been observed in patients taking intravenous or subcutaneous ACTEMRA. Some of these cases have resulted in liver transplant or death. Time to onset for cases ranged from months to years after treatment initiation. Most cases presented with marked elevations of transaminases (> 5 times ULN), and some cases presented with signs or symptoms of liver dysfunction and only mildly elevated transaminases.

Treatment with ACTEMRA was associated with a higher incidence of transaminase elevations; increased frequency and magnitude of these elevations were observed when ACTEMRA was used in combination with potentially hepatotoxic drugs (e.g., methotrexate).

It is not recommended to initiate ACTEMRA treatment in RA, GCA, PJIA, SJIA and SSc-ILD patients with elevated transaminases ALT or AST greater than 1.5x ULN. In patients who develop elevated ALT or AST greater than 5x ULN discontinue ACTEMRA.

It is not recommended to initiate ACTEMRA treatment in COVID-19 patients with elevated ALT or AST above 10 x ULN. ALT and AST should be monitored according to current standard clinical practice for COVID-19 patients.

Measure liver tests promptly in patients who report symptoms that may indicate liver injury. If the patient is found to have abnormal liver tests, ACTEMRA treatment should be interrupted. ACTEMRA should only be restarted in patients with another explanation for the liver test abnormalities after normalization of the liver tests.

Laboratory Parameters

Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Dosage modifications may be required.

Neutropenia: Treatment with ACTEMRA was associated with a higher incidence of neutropenia. It is not recommended to initiate ACTEMRA treatment in RA, GCA, PJIA, SJIA and SSc-ILD patients with a low neutrophil count i.e., absolute neutrophil count (ANC) less than 2000 per mm³. In patients who develop an ANC less than 500 per mm³ treatment is not recommended.

It is not recommended to initiate ACTEMRA treatment in COVID-19 patients with an ANC less than 1000 per mm³. Neutrophils should be monitored according to current standard clinical practice.

Thrombocytopenia: Treatment with ACTEMRA was associated with a reduction in platelet counts. It is not recommended to initiate ACTEMRA in RA, GCA, PJIA, SJIA and SSc-ILD patients with a platelet count below 100,000 per mm³. In patients who develop a platelet count less than 50,000 per mm³, treatment is not recommended.

In COVID-19 patients who develop a platelet count less than 50,000 per mm³ treatment is not recommended. Platelets should be monitored according to current standard clinical practices.

Elevated Liver Enzymes: It is not recommended to initiate ACTEMRA treatment in patients with elevated transaminases ALT or AST >1.5x ULN. In patients who develop elevated ALT or AST >5x ULN, treatment is not recommended.

Lipid Abnormalities: Treatment with ACTEMRA was associated with increases in lipid parameters such as total cholesterol, triglycerides, LDL cholesterols, and/or HDL cholesterol.

Immunosuppression

The impact of treatment with ACTEMRA on the development of malignancies is not known, but malignancies were observed in clinical studies with ACTEMRA. ACTEMRA is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies.

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in association with ACTEMRA and anaphylactic events with a fatal outcome have been reported with intravenous infusion of ACTEMRA. In addition, serious cutaneous reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported in patients with autoinflammatory conditions treated with ACTEMRA. ACTEMRA for intravenous use should only be infused by a healthcare professional with appropriate medical support to manage anaphylaxis. For ACTEMRA subcutaneous injection, advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. If a hypersensitivity reaction occurs, immediately discontinue ACTEMRA, treat promptly and monitor until signs and symptoms resolve.

Anaphylaxis and other hypersensitivity reactions that required treatment discontinuation were reported in 0.1% (3 out of 2644) of patients in the 6-month controlled trials of intravenous ACTEMRA, 0.2% (8 out of 4009) of patients in the intravenous all-exposure RA population, 0.7% (8 out of 1068) in the subcutaneous 6-month controlled RA trials, and in 0.7% (10 out of 1465) of patients in the subcutaneous all-exposure population. In the SJIA controlled trial with intravenous ACTEMRA, 1 out of 112 patients (0.9%) experienced hypersensitivity reactions that required treatment discontinuation. In the PJIA controlled trial with intravenous ACTEMRA, 0 out of 188 patients (0%) in the ACTEMRA all-exposure population experienced hypersensitivity reactions that required treatment discontinuation.

Demyelinating Disorders

The impact of treatment with ACTEMRA on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies. Monitor patients for signs and symptoms of demyelinating disorders. Prescribers should exercise caution in considering the use of ACTEMRA in patients with preexisting or recent-onset demyelinating disorders.

Active Hepatic Disease and Hepatic Impairment

Treatment with ACTEMRA is not recommended in patients with active hepatic disease or hepatic impairment.

Vaccinations

Avoid use of live vaccines concurrently with ACTEMRA. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving ACTEMRA or on the effectiveness of vaccination in patients receiving ACTEMRA. Patients should be brought up to date on all recommended vaccinations prior to initiation of ACTEMRA therapy, if possible.

ADVERSE REACTIONS

RHEUMATOID ARTHRITIS (RA)

The most common serious adverse reactions were serious infections. The most common serious infections included pneumonia, urinary tract infection, cellulitis, herpes zoster, gastroenteritis, diverticulitis, sepsis and bacterial arthritis. In the ACTEMRA-IV monotherapy clinical study, the rate of serious infections was 3.6 per 100 patient-years in the ACTEMRA group and 1.5 per 100 patient-years in the methotrexate group. The rate of serious infections in the 4 mg/kg and 8 mg/kg ACTEMRA plus DMARD groups was 4.4 and 5.3 events per 100 patient-years, respectively, compared to 3.9 events per 100 patient-years in the placebo plus DMARD group.

In the 5 Phase III clinical trials, the most common adverse reactions (≥5% of patients treated with ACTEMRA-IV) through 6 months were:

	ACTEMRA-IV 8 mg/kg Monotherapy (%)	Methotrexate (%)	ACTEMRA-IV 4 mg/kg + DMARDs (%)	ACTEMRA-IV 8 mg/kg + DMARDs (%)	Placebo + DMARDs (%)
URTI	7	5	6	8	6
Nasopharyngitis	7	6	4	6	4
Headache	7	2	6	5	3
Hypertension	6	2	4	4	3
Increased ALT	6	4	3	3	1

The safety observed for ACTEMRA administered subcutaneously was consistent with the known safety profile of intravenous ACTEMRA, with the exception of injection-site reactions, which were more common with ACTEMRA-SC compared with placebo-SC injections (IV-arm).

In the 6-month control period, in SC-I, the frequency of injection-site reactions was 10.1% (64/631) and 2.4% (15/631) for the weekly ACTEMRA-SC and placebo-SC (IV-arm) group, respectively. In SC-II, the frequency of injection-site reactions was 7.1% (31/437) and 4.1% (9/218) for the every other week ACTEMRA-SC and placebo-SC groups, respectively. These injection-site reactions were mild to moderate in severity. The majority resolved without any treatment and none necessitated drug discontinuation.

GIANT CELL ARTERITIS (GCA)

The overall safety profile observed in the ACTEMRA treatment groups was generally consistent with the known safety profile of ACTEMRA. There was an overall higher incidence of infections in GCA patients relative to RA patients.

Infections

The rate of infections was 200.2 per 100 patient-years in the ACTEMRA SC weekly group and 160.2 per 100 patient-years in the ACTEMRA SC every other week group, as compared to 156.0 per 100 patient-years in the placebo + 26 week prednisone taper and 210.2 per 100 patient-years in the placebo + 52 week taper groups.

The rate of serious infections was 9.7 per 100 patient-years in the ACTEMRA SC weekly group and 4.4 per 100 patient-years in the ACTEMRA SC every other week group, as compared to 4.2 per 100 patient-years in the placebo + 26 week prednisone taper and 12.5 per 100 patient-years in the placebo + 52 week prednisone taper groups.

POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA)

The most common adverse events seen in ACTEMRA-IV all-exposure population included: upper respiratory tract infections, headache, nasopharyngitis, and diarrhea.

Infections

The rate of infections in the ACTEMRA-IV all-exposure population was 163.7 per 100 patient-years. The most common events observed were nasopharyngitis and upper respiratory tract infections. The rate of serious infections was numerically higher in patients weighing less than 30 kg treated with 10 mg/kg ACTEMRA-IV (12.2 per 100 patient-years) compared to patients weighing at or above 30 kg, treated with 8 mg/kg ACTEMRA-IV (4.0 per 100 patient-years). The incidence of infections leading to dose interruptions was also numerically higher in patients weighing less than 30 kg treated with 10 mg/kg ACTEMRA-IV (21%) compared to patients weighing at or above 30 kg, treated with 8 mg/kg ACTEMRA-IV (8%).

Infusion Reactions

In PJIA patients, infusion-related reactions are defined as all events occurring during or within 24 hours of an infusion. In the ACTEMRA-IV all-exposure population, 11 patients (6%) experienced an event during the infusion, and 38 patients (20.2%) experienced an event within 24 hours of an infusion. The most common events occurring during infusion were headache, nausea and hypotension, and occurring within 24 hours of infusion were dizziness and hypotension.

In general, the safety observed for ACTEMRA administered subcutaneously was consistent with the known safety profile of intravenous ACTEMRA, with the exception of injection site reactions (ISRs), and neutropenia.

During the 1-year study, a frequency of 28.8% (15/52) ISRs was observed in ACTEMRA-SC treated PJIA patients. These ISRs occurred in a greater proportion of patients at or above 30 kg (44.0%) compared with patients below 30 kg (14.8%). All ISRs were mild in severity and none of the ISRs required patient withdrawal from treatment or dose interruption.

During routine laboratory monitoring in the ACTEMRA-SC all exposure population, a decrease in neutrophil counts below 1 × 10⁹ per L occurred in 15.4% of patients, and was more frequently observed in the patients less than 30 kg (25.9%) compared to patients at or above 30 kg (4.0%). There was no clear relationship between decreases in neutrophils below 1 x 10⁹ per L and the occurrence of serious infections.

SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA)

The most common adverse events (at least 5%) seen in ACTEMRA-IV treated patients in the 12-week controlled portion of the study were: upper respiratory tract infections, headache, nasopharyngitis, and diarrhea.

Infections

In the 12-week controlled phase, the rate of all infections in the ACTEMRA-IV group was 345 per 100 patient-years and 287 per 100 patient-years in the placebo group. In the open-label extension over an average duration of 73 weeks of treatment, the overall rate of infections was 304 per 100 patient-years.

In the 12-week controlled phase, the rate of serious infections in the ACTEMRA-IV group was 11.5 per 100 patient-years. In the open-label extension over an average duration of 73 weeks of treatment, the overall rate of serious infections was 11.4 per 100 patient-years. The most commonly reported serious infections included pneumonia, gastroenteritis, varicella, and otitis media.

Macrophage Activation Syndrome

In the 12-week controlled study, no patient in any treatment group experienced macrophage activation syndrome (MAS) while on assigned treatment; 3 per 112 (3%) developed MAS during open-label treatment with ACTEMRA-IV. One patient in the placebo group escaped to ACTEMRA-IV 12 mg per kg at Week 2 due to severe disease activity, and ultimately developed MAS at Day 70. Two additional patients developed MAS during the long-term extension. All 3 patients had ACTEMRA-IV dose interrupted (2 patients) or discontinued (1 patient) for the MAS event, received treatment, and the MAS resolved without sequelae. Based on a limited number of cases, the incidence of MAS does not appear to be elevated in the ACTEMRA-IV SJIA clinical development experience; however, no definitive conclusions can be made.

Infusion Reactions

In the 12-week controlled phase, 4% of ACTEMRA-IV and 0% of placebo-treated patients experienced events occurring during infusion.

Within 24 hours after infusion, 16% of patients in the ACTEMRA-IV treatment group and 5% of patients in the placebo group experienced an event. In the ACTEMRA-IV group the events included rash, urticaria, diarrhea, epigastric discomfort, arthralgia, and headache. One of these events, urticaria, was considered serious.

Anaphylaxis

Anaphylaxis was reported in 1 out of 112 patients (less than 1%) treated with ACTEMRA-IV during the controlled and open-label extension study.

In general, the safety observed for ACTEMRA administered subcutaneously was consistent with the known safety profile of intravenous ACTEMRA, with the exception of Injection Site Reactions (ISRs).

A total of 41.2% (21/51) SJIA patients experienced ISRs to ACTEMRA-SC. The most common ISRs were erythema, pruritus, pain, and swelling at the injection site. The majority of ISRs reported were Grade 1 events and all ISRs reported were non-serious and none required patient withdrawal from treatment or dose interruption.

CORONAVIRUS DISEASE 2019 (COVID-19)

The safety of ACTEMRA in hospitalized COVID-19 patients was evaluated in a pooled safety population that includes patients enrolled in EMPACTA, COVACTA, and REMDACTA. The analysis of adverse reactions included a total of 974 patients exposed to ACTEMRA:

Adverse Reaction	ACTEMRA 8 mg per kg N = 974 (%)	Placebo N = 483 (%)
Hepatic Transaminases increased	10%	8%
Constipation	9%	8%
Urinary tract infection	5%	4%
Hypertension	4%	1%
Hypokalaemia	4%	3%
Anxiety	4%	2%
Diarrhoea	4%	2%
Insomnia	4%	3%
Nausea	3%	2%

In the pooled safety population, the rates of infection/serious infection events were 40%/19% in patients receiving ACTEMRA versus 32%/23% receiving placebo.

Laboratory Abnormalities

In the pooled safety population of EMPACTA, COVACTA, and REMDACTA, neutrophil counts <1000 cells/mcl occurred in 3.4% of patients who received ACTEMRA and 0.5% of patients who received placebo. Platelet counts <50,000 cells/mcl occurred in 3.2% of patients who received ACTEMRA and 1.5% of patients who received placebo. ALT or AST at or above 5x ULN occurred in 11.7% of patients who received ACTEMRA and 9.9% of patients who received placebo.

DRUG INTERACTIONS

In GCA patients, no effect of concomitant corticosteroid on ACTEMRA exposure was observed.

Cytochrome P450s in the liver are down-regulated by infection and inflammation stimuli including cytokines such as IL-6. Inhibition of IL-6 signaling in RA patients treated with ACTEMRA may restore CYP450 activities to higher levels than those in the absence of ACTEMRA leading to increased metabolism of drugs that are CYP450 substrates.

Exercise caution when coadministering ACTEMRA with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.

USE IN PREGNANCY

The available data with ACTEMRA in pregnant women are insufficient to draw conclusions about drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see additional Important Safety Information in full Prescribing Information, including BOXED WARNING.

- ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
  
  ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
- Jones G, et al. Ann Rheum Dis. 2010;69:88-96.
  
  Jones G, et al. Ann Rheum Dis. 2010;69:88-96.
- Kremer JM, et al. Arthritis Rheumatol. 2018;70(8):1200-1208.
  
  Kremer JM, et al. Arthritis Rheumatol. 2018;70(8):1200-1208.
- Maini RN, et al. Arthritis Rheum. 2006;54(9):2817-2829.
  
  Maini RN, et al. Arthritis Rheum. 2006;54(9):2817-2829.
- Bykerk VP, et al. Ann Rheum Dis. 2012;71:1950-1954.
  
  Bykerk VP, et al. Ann Rheum Dis. 2012;71:1950-1954.
- Dougados M, et al. Ann Rheum Dis. 2013;72:43-50.
  
  Dougados M, et al. Ann Rheum Dis. 2013;72:43-50.
- Weinblatt ME. Arthritis Care Res. 2013;65(3):362-371.
  
  Weinblatt ME. Arthritis Care Res. 2013;65(3):362-371.
- Ogata A, et al. Arthritis Care Res. 2014;66(3):344-354.
  
  Ogata A, et al. Arthritis Care Res. 2014;66(3):344-354.
- Gabay C, et al. Lancet. 2013;381:1541-1550.
  
  Gabay C, et al. Lancet. 2013;381:1541-1550.
- Emery P, et al. Ann Rheum Dis. 2008;67:1516-1523.
  
  Emery P, et al. Ann Rheum Dis. 2008;67:1516-1523.
- Burmester GR, et al. Ann Rheum Dis. 2014;73:69-74.
  
  Burmester GR, et al. Ann Rheum Dis. 2014;73:69-74.
- Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
  
  Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
- Genovese MC, et al. Arthritis Rheum. 2008;58(10):2968-2980.
  
  Genovese MC, et al. Arthritis Rheum. 2008;58(10):2968-2980.
- Data on file. Clinical Study Report. Genentech, Inc.
  
  Data on file. Clinical Study Report. Genentech, Inc.
- Kivitz A, et al. Arthritis Care Res. 2014;66(11):1653-1661.
  
  Kivitz A, et al. Arthritis Care Res. 2014;66(11):1653-1661.
- Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.
  
  Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.
- De Benedetti F, et al. N Engl J Med. 2012;367:2385-2395.
  
  De Benedetti F, et al. N Engl J Med. 2012;367:2385-2395.
- Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
  
  Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
- Yazici Y, et al. Ann Rheum Dis. 2012;71:198-205.
  
  Yazici Y, et al. Ann Rheum Dis. 2012;71:198-205.
- Bingham CO, et al. Ann Rheum Dis. 2014;74:818-822.
  
  Bingham CO, et al. Ann Rheum Dis. 2014;74:818-822.
- Smolen JS, et al. Lancet. 2008;371:987-997.
  
  Smolen JS, et al. Lancet. 2008;371:987-997.
- Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.
  
  Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.
- McGrath H, et al. Rheumatology. 2004;43:1323-1325.
  
  McGrath H, et al. Rheumatology. 2004;43:1323-1325.
- Browning JL, et al. Nat Rev Discov. 2006;5:564-576.
  
  Browning JL, et al. Nat Rev Discov. 2006;5:564-576.
- Choy, E, et al. Rheum Dis Clin N Am. 2004;30:405-415.
  
  Choy, E, et al. Rheum Dis Clin N Am. 2004;30:405-415.
- Data on file. LITHE Clinical Study Report. Genentech, Inc.
  
  Data on file. LITHE Clinical Study Report. Genentech, Inc.
- Data on file. ACTEMRA Studies Matrix. Genentech, Inc.
  
  Data on file. ACTEMRA Studies Matrix. Genentech, Inc.
- Data on file. PBRER Core Report. Genentech, Inc.
  
  Data on file. PBRER Core Report. Genentech, Inc.
- Data on file, Genentech, Inc.
  
  Data on file, Genentech, Inc.
- Genentech Analysis of Managed Markets Insight & Technology (MMIT) Data.
  
  Genentech Analysis of Managed Markets Insight & Technology (MMIT) Data.
- HUMIRA [package insert]. North Chicago, IL; AbbVie Inc.
  
  HUMIRA [package insert]. North Chicago, IL; AbbVie Inc.
- Data on file. RADIATE CSR. Genentech, Inc.
  
  Data on file. RADIATE CSR. Genentech, Inc.